Lead Product(s): Pegfilgrastim
Therapeutic Area: Hematology Product Name: Nyvepria
Highest Development Status: Approved Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 11, 2020
The FDA approval was based on the review of a comprehensive data package and totality of evidence demonstrating a high degree of similarity of NYVEPRIA to its reference product.
Lead Product(s): Abelacimab
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Anthos Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership June 11, 2020
The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.